TP53 and liver cancer: To examine whether JMJD2D could interact with p53 protein to inhibit its DNA binding activity in liver cancer cells, we performed co-immunoprecipitation (Co-IP) assay using anti-JMJD2D and anti-p53 antibodies, respectively.